BMF-219 is under clinical development by Biomea Fusion and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BMF-219’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BMF-219 is under development for the treatment of relapsed and refractory leukemia including mixed-lineage leukemia rearrangement (MLL-r) acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, relapsed and refractory chronic lymphocytic leukemia, NPM1 mutant acute myeloid leukemia, KRAS mutant solid tumors including colorectal, non-small cell lung cancer, pancreatic ductal adenocarcinoma diffuse large B-cell lymphoma (DLBCL), multiple myeloma, lung and pancreatic tumors. The drug is administered through oral route. It acts by targeting menin. It is under development for type 1/2 diabetes.
Biomea Fusion overview
Biomea Fusion is a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers. The company is headquartered in Palo Alto, California, the US.
For a complete picture of BMF-219’s drug-specific PTSR and LoA scores, buy the report here.